RANI Stock Analysis: Buy, Sell, or Hold?
RANI - Rani Therapeutics Holdings, Inc. Class A Common Stock
$0.74
-0.02 (-3.22%)
▼
5d:
-2.99%
30d:
-21.07%
90d:
-34.89%
HOLD
MODERATE Confidence
Analysis Updated: Jun 25, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When RANI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RANI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RANI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RANI is currently trading at $0.74, which is considered slightly low relative to its 30-day fair value range of $0.77 to $0.97.
Technical Outlook: Technically, RANI is in a strong downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: RANI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.50 (+910.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RANI is in a strong downtrend. The price is currently testing key support at $0.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: RANI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.50 (+910.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.77 -
$0.97
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 910.4% below Wall St target ($7.50)
Trading Range Analysis
30-Day Trading Range
$0.77 -
$0.97
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$0.99
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.37
Wall Street Target
$7.50
(+910.4%)
Revenue Growth (YoY)
893.0%
Share & Embed Analysis
Last updated: June 25, 2026 9:00 PM ET
Data refreshes hourly during market hours. Next update: 10:00 PM
Data refreshes hourly during market hours. Next update: 10:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RANI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 64 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 62 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 59 HOLD |
